MEAI

SciSparc Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic-Based Treatment

Retrieved on: 
Tuesday, November 28, 2023
Hebrew University of Jerusalem, Blood, MEAI, Depression, TEL, CWY, Combination, Animal, Appetite, Obesity, PEA, Central nervous system, Carbon, Safety, Therapy, Disorder, Pharmaceutical industry

TEL AVIV, Israel, Nov. 28, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, today announced successful results from a pre-clinical trial performed by Professor Joseph Tam from The Hebrew University of Jerusalem.

Key Points: 
  • The combination treatment includes palmitoylethanolamide (PEA), an anti-inflammatory agent and the active ingredient of the Company’s proprietary CannAmide™, and MEAI, Clearmind’s novel proprietary psychedelic treatment for various addictions, obesity, and depression (the “Combination Treatment”).
  • The administered treatment exhibited a meaningful degree of tolerance, leaving the mice's viability unaffected across all experimental groups.
  • The changed rates of oxygen consumption and carbon dioxide emission indicate increases in the metabolic process and fat burn.
  • "The trial's findings, including increased metabolic activity, reduced appetite, and enhanced fat oxidation, are promising indicators of the treatment's efficacy and safety."

Clearmind Medicine Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic- Based Treatment

Retrieved on: 
Tuesday, November 28, 2023
Hebrew University of Jerusalem, Blood, MEAI, Motivation, Depression, Weight, Weight loss, Mouse, CWY, Clinical trial, Hospital, Animal, DSM-IV codes, Appetite, Obesity, PEA, Carbon, Safety, Therapy

Tel Aviv, Israel / Vancouver, Canada, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced today positive results from its pre-clinical trial led by Professor Joseph Tam from The Hebrew University of Jerusalem.

Key Points: 
  • Results indicated that:
    The administered treatment exhibited a remarkable degree of tolerance, leaving the mice' viability unaffected across all experimental groups.
  • "We are excited by these latest results of our combination treatment for obesity and metabolic disorders.
  • These latest results strengthen our confidence in our MEAI-based treatment, including our combination treatment with SciSparc's PEA."
  • "These results from the pre-clinical trial highlight the promising potential of Clearmind's MEAI and SciSparc's PEA combination treatment for obesity and metabolic disorders.

Clearmind Medicine to Participate in Traditional vs. Novel Psychedelics Virtual Event with Leading Industry Figures

Retrieved on: 
Monday, November 27, 2023
MEAI, MSW, MAPS, CWY, Doctor of Philosophy, Drug policy, Therapy

Tel Aviv, Israel / Vancouver, Canada, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, will participate in a special virtual event to discuss the current psychedelic renaissance that is opening the doors to the benefits of both traditional and novel psychedelics, as older therapies are being re-examined and new molecules are being identified for current and future clinical studies.

Key Points: 
  • The virtual event will be held on Wednesday, Nov 29, 2023 at 12pm EST/ 9am PST.
  • The virtual event is part of The Psychedelic Association of Canada (PAC) "Industry Presents" Series.
  • Clearmind's CEO, Adi Zuloff-Shani, PhD, will share her thoughts about the Company's innovative MEAI molecule, defined as novel psychedelics.
  • Mark Haden, MSW, VP of business development for Clearmind Medicine, will take part in the event as well.

Clearmind Medicine to Pioneer Psychedelic Clinical Trials for Alcohol Use Disorder with Ivy League Universities

Retrieved on: 
Thursday, November 9, 2023
Patient, Clinical trial, Health, Crave, Psychiatry, MEAI, Safety, Depression, Johns Hopkins School of Medicine, AUD, Pharmaceutical industry

Tel Aviv, Israel / Vancouver, Canada, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. is pleased to announce that the company has entered into a Clinical Trial Agreement with Johns Hopkins University School of Medicine, to conduct its Phase I/IIa clinical trial of its proprietary MEAI-based CMND-100 as a potential treatment for Alcohol Use Disorder (AUD). The CM-CMND-001 clinical trial is a multinational, multi-center, single- and multiple-dose tolerability, safety and pharmacokinetic study in healthy volunteers and AUD subjects.

Key Points: 
  • The CM-CMND-001 clinical trial is a multinational, multi-center, single- and multiple-dose tolerability, safety and pharmacokinetic study in healthy volunteers and AUD subjects.
  • The patients will report their drinking patterns and craving for alcohol (and cigarettes) during the clinical trial period.
  • Johns Hopkins University School of Medicine is the second US-based medical site to join the Company’s clinical trial.
  • The potential of psychedelic drugs to treat various neuropsychiatric indications is currently being explored in multiple human clinical trials.

Clearmind Medicine Announces Clinical Research Collaboration with Johns Hopkins University to Evaluate CMND-100 in Patients with Alcohol Use Disorder

Retrieved on: 
Wednesday, September 6, 2023
CSE, Therapy, Johns Hopkins School of Medicine, Clinical trial, MEAI, FSE, Doctor of Philosophy, Associate, JHU, Crave, AUD, Patient, CWY, Pharmacology, Psychiatry, Behavioural sciences, Johns Hopkins, Safety, Pharmaceutical industry, Medicine

"We are honored to collaborate with JHU for our first in human clinical trial.

Key Points: 
  • "We are honored to collaborate with JHU for our first in human clinical trial.
  • "Johns Hopkins is our second US clinical site joining our trial, following Yale School of Medicine’s Department of Psychiatry.
  • The patients will report their drinking patterns and craving for alcohol (and cigarettes) during the clinical trial period.
  • CM-CMND-001 clinical trial is a multinational, multi-center, Phase I/II single- and multiple-dose tolerability, safety and pharmacokinetic study in healthy volunteers and AUD subjects.

Clearmind Medicine Files Patent Application with USPTO for the Treatment of Dyskinesia; Further Strengthens its Already Robust IP Portfolio

Retrieved on: 
Tuesday, August 1, 2023
Patent, Extremities, CSE, Obesity, Therapy, Face, United States Patent and Trademark Office, DSM-IV codes, MEAI, Dystonia, FSE, Disorder, Parkinson's disease, Patient, CWY, Myenteric plexus, Chorea, Pharmaceutical industry, Dyskinesia

The patent application refers to the psychedelic molecule 3-Methylmethcathinone ("3-MMC”) as a potential treatment for Dyskinesia thus expanding Clearmind’s IP portfolio for innovative molecules, new indications and treatments.

Key Points: 
  • The patent application refers to the psychedelic molecule 3-Methylmethcathinone ("3-MMC”) as a potential treatment for Dyskinesia thus expanding Clearmind’s IP portfolio for innovative molecules, new indications and treatments.
  • "Clearmind continues to strengthen its position as a leader in the psychedelic-derived therapeutics industry through an aggressive strategy to expand our IP portfolio.
  • Clearmind has a broad IP footprint in the psychedelic space with 30 patents and patent applications across 14 patent families, nine of which have been granted in major jurisdictions like the US, Europe, China, and India.
  • The company has already filed patent applications for the combination of Clearmind's MEAI with SciSparc's Palmitoylethanolamide for treating alcohol use disorder, cocaine addiction, and obesity, as well as related metabolic disorders.

Dr. Fatima Cody Stanford, Associate Professor of Medicine and Pediatrics at Harvard Medical School, Joins Clearmind Medicine's Scientific Advisory Board

Retrieved on: 
Tuesday, July 11, 2023
Emory University, Obesity, CSE, Harvard Kennedy School, Pediatrics, Hebrew University of Jerusalem, Therapy, Obesity medicine, Public, Medical college, Policy, Weight loss, MEAI, Al-Quds, Business, Master of Public Administration, Coronavirus Scientific Advisory Board, FSE, Quantic School of Business and Technology, Associate, Harvard Medical School, Public health, Animal, MD, Metabolic syndrome, CWY, Motivation, Liver, Hospital, Massachusetts General Hospital, Master, Pharmaceutical industry, Management, Science, Medicine

Dr. Stanford is currently associated with Massachusetts General Hospital and is an Associate Professor of Medicine and Pediatrics at Harvard Medical School, where she serves as an educator, researcher, and policy maker.

Key Points: 
  • Dr. Stanford is currently associated with Massachusetts General Hospital and is an Associate Professor of Medicine and Pediatrics at Harvard Medical School, where she serves as an educator, researcher, and policy maker.
  • Dr. Stanford completed her Obesity Medicine & Nutrition Fellowship at Massachusetts General Hospital and Harvard Medical School, further enhancing her expertise in the field.
  • With a career dedicated to bridging the gaps between medicine, public health, and policy, Dr. Stanford has become a sought-after expert in obesity medicine, both nationally and internationally.
  • "We are delighted to welcome Dr. Fatima Cody Stanford to our Scientific Advisory Board.

Clearmind Medicine and SciSparc to Conduct Study Evaluating Combination Treatment for Obesity and Metabolic Syndrome

Retrieved on: 
Friday, June 16, 2023
Obesity, CSE, Central nervous system, Depression, Hebrew University of Jerusalem, Therapy, Metabolism, Weight loss, MEAI, Al-Quds, FSE, Research, Cannabinoid, Human, PEA, Animal, Patent, Metabolic syndrome, CWY, Motivation, Liver, Cocaine, Pharmaceutical industry, Dietary supplement, Yissum Research Development Company of the Hebrew University

Tel Aviv, Israel / Vancouver, Canada, June 16, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that as part of the Company's ongoing collaboration with SciSparc Ltd. (NASDAQ: SPRC) ("SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, it has entered into a research agreement with the Hebrew University of Jerusalem, to evaluate Clearmind's and SciSparc's combination treatment for obesity and metabolic syndrome.

Key Points: 
  • "We are excited to further investigate the effect of the combination of MEAI and PEA for treating obesity and metabolic syndrome.
  • Previous pre-clinical studies performed with our proprietary MEAI showed a very positive effect in treating obesity.
  • "The collaboration with SciSparc has already yielded numerous patent applications related to combination therapies for treating binge behaviors, cocaine addiction, depression and more."
  • The upcoming study will evaluate the effect of the combination of MEAI and PEA on food intake, metabolic and activity profiles.

SciSparc and Clearmind Medicine to Conduct a Study Evaluating Their Combination Treatment for Obesity and Metabolic Syndrome

Retrieved on: 
Friday, June 16, 2023
Obesity, CSE, Central nervous system, Hebrew University of Jerusalem, Therapy, Metabolism, Weight loss, Al-Quds, MEAI, Global health, Research, Cannabinoid, PEA, Animal, Metabolic syndrome, Motivation, Liver, Human, Pharmaceutical industry, Dietary supplement

Tel Aviv, Israel, June 16, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that as part of the Company's ongoing collaboration with Clearmind Medicine Inc. (NASDAQ, CSE: CMND) ("Clearmind"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, a research agreement with the Hebrew University of Jerusalem was signed, to evaluate SciSparc's and Clearmind's proprietary combination treatment for obesity and metabolic syndrome.

Key Points: 
  • "We are excited to continue our fruitful journey of scientific discovery alongside Clearmind Medicine and the esteemed Professor Joseph Tam of the Hebrew University of Jerusalem," stated Oz Adler, Chief Executive Officer of SciSparc.
  • "We believe that the synergistic effect of our proprietary CannAmide™ and Clearmind's proprietary MEAI has immense potential in treating obesity and metabolic syndrome, two global health challenges of significant scale.
  • Additionally, the treatment yielded a normalization of insulin levels, improved glucose tolerance, and reduced fat and triglyceride accumulation in the liver.
  • Thus, MEAI may be beneficial for the treatment of compulsive reward-seeking behavior or excessive consumption of sweet foods.

Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity

Retrieved on: 
Friday, June 9, 2023
Business development, Obesity, CSE, Therapy, Metabolism, Drug development, MEAI, FSE, Associate, Hebrew language, Metabolic syndrome, CWY, Pharmaceutical industry, Pharmacology

Tel Aviv, Israel / Vancouver, Canada, June 09, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the Company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, will host a virtual investor conference titled “Psychedelics for Obesity” on Monday, June 12th, at 10:00 AM EST.

Key Points: 
  • The conference will stream live on Monday, June 12, at 10:00 AM EST
    Tel Aviv, Israel / Vancouver, Canada, June 09, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the Company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, will host a virtual investor conference titled “Psychedelics for Obesity” on Monday, June 12th, at 10:00 AM EST.
  • Clearmind recently announced positive pre-clinical results demonstrating efficacy of its drug candidate MEAI for treating obesity and metabolic syndrome.
  • Professor Tam will headline the conference discussing the challenges of obesity and the promising pre-clinical results for MEAI as a potential treatment.
  • The conference will also feature Mark Haden, Clearmind's VP of Business Development, and will be hosted by Shannon Smadella of Clearmind’s Community Development department.